Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00040638

Enrollment

Registered

2002-07-04

Start date

2002-07-31

Completion date

2003-08-31

Last updated

2011-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-small-cell Lung

Brief summary

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Interventions

DRUGTLK286

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologic or cytologic diagnosis of non-small cell lung carcinoma * Progressed while on or after treatment on platinum-based regimen * Patients may not have had more than one prior cytotoxic chemotherapy regimen * Stage IV or IIIB * Age at least 18 years * Adequate liver and kidney function * Adequate bone marrow function

Exclusion criteria

* Pregnancy or lactation * Unstable medical conditions * Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286 * CNS metastasis unless controlled by treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026